Dissecting Perioperative Immunotherapy Approaches in Early-Stage NSCLC - Episode 1

How Immunotherapy Is Affecting Perioperative Treatment Decisions in Early-Stage NSCLC

July 17, 2025

Wade T. Iams, MD, Jessica Donington, MD, MSCR

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy is affecting perioperative treatment in early-stage non–small cell lung cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Now Viewing

EP. 1: How Immunotherapy Is Affecting Perioperative Treatment Decisions in Early-Stage NSCLC

EP. 2: Perioperative Nivolumab in Resectable NSCLC: Updated Data From CheckMate-77T

EP. 3: Surgical Outcomes From CheckMate-77T With Perioperative Nivolumab in Resectable NSCLC

EP. 4: Updated Findings From CheckMate-816 for Neoadjuvant Nivolumab Plus Chemo in Resectable NSCLC

EP. 5: Factors Influencing Adjuvant Treatment Decisions in Early-Stage NSCLC

EP. 6: How Immunotherapy Could Continue to Affect Early-Stage NSCLC Management

EP. 7: Unmet Needs Research Aims to Address in Early-Stage NSCLC